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Arteether, a qinghaosu derivative, 
in toxoplasmosis 
H. R. Chang and J.-C. Pechkre Department of 
Microbiolow. Universitv of Geneva Medical School, 
Centre M&&l Universkzi~e, 1211 Geneva 4, Switzerl 
land 
Toxoplasmic encephalitis a common and life- 
threatening occurrence in patients with acquired 
immunodeficiency syndrome (AIDS). The current 
treatment of choice is the combination of pyrimetha- 
mine and sulfadiazine. This combination, -however, 
while beine hiehlv effective aaainst he disease, has 
the incon&&& of being associated with a -high 
incidence of side effects which often require with- 
drawal of therapy. Therefore, there is an urgent need 
for newer and safer therapy for this disease. 
Arteether is an ethyl ether derivative ofqinghaosu 
(QHS) (BROW et al., 1988). QHS is a naturally 
occurring sesquiterpene lactone which has been iso- 
lated from the traditional Chinese herb Artemisia 
amwu (KLAYMAN, 1985), the structure of which 
includes aperoxide ring. QHS has been found active 
in in vitro and in vivo models against Plasmodium 
(PETERS et al., 1986), and in vitro against Naegleriu 
fmleri (COOKE et al.. 1987). Interestinelv, OHS 
crosses the blood-brain barrier and is also’ effective 
against cerebral malaria (LX et al., 1984). Because 
Toxoplasma g&ii is also a protozoon, we tested the 
activity ofQHS against his parasite using an in vitro 
and in vivo model. Unelicited mouse peritoneal 
macrophages were used to test the anti-Toxopluma 
activity ofarteether as previously described (CHANG 
& PECHI%E, 1988). Macrophage monolayers were 
infected with T. go&ii for 1 h, washed twice, and 
incubated for 18 h with media containing arteether in
concentrations from 0.01 to 400 &ml. Preliminary 
results uggested that arteether had some inhibitory 
effect on Toxoplasma renlication bv diminishina the 
number of infected cells-and the number of Toxc$as- 
m42 per 100 cells in concentrations a low as 0.1 pgi 
ml. Further experiments howed, however, that these 
results were not reproducible. We have no explana- 
tion for this, as these macrophages were obtained 
from pathogen-free and Toxoplusmu serologically 
negative mice. Moreover, arteether xerted no inhibi- 
to& activity on the incorporation f [3H]uracil by 
intracellular T. mndii in concentrations from 0.01 to 
400 pg/ml. We‘kmphasize, therefore, that both sys- 
tems are complementary and must be used together, 
when oossible. for assessina the in vitro activitv of 
compounds against T. gun&. 
Swiss-Webster female mice were infected intraoeri- 
toneally with 5 x IO3 tachyzoites ofthe highly virulent 
RH strain of T. g&ii (CHANG & PECHBRE, 1987). 24 
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h later, arteether was administered subcutaneously 
at daily doses of 1, 10, 25, 50, 100, 200, 400 and 
600 mg/kg for 5 d. All untreated control mice died 
7+ 1 d after challenge, asdid all mice treated with up 
to 100 mg/kg. WidZ&l mg/kg there was an increase 
in survival. 20% of mice livina until the 15th dav after 
challenge, ‘but all died of tocoplasmosis on the 16th 
day, as demonstrated by autopsy. Mice treated with 
4ob and 600 mg/kg, however, presented acute signs 
of toxicitv after the 2nd dav of theranv. Theranv was 
therefore* stopped on this day, and all the *mice 
receiving 406 ;ng/kg died 10 h after challenge; all 
those receivine 600 make died 4 d after challenge. 
As positive co&ols, ideckd mice were treated or&y 
with 330 mg/kg of roxithromycin for 5 d 
(SDSo=336 mg/kgx5 d; CHANG & PECH&E, 1987), 
which afforded 71.4% protection, orwith A-56268, a 
new macrolide, at a dose of 300 mg/kg for 9 d, which 
afforded 100% protection (CHANG et al., 1988). 
The results of this investigation suggest that 
arteether would not be useful in the treatment of 
toxoplasmosis. 
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